» Articles » PMID: 30883541

Building a Mechanistic Mathematical Model of Hepatitis C Virus Entry

Overview
Specialty Biology
Date 2019 Mar 19
PMID 30883541
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

The mechanism by which hepatitis C virus (HCV) gains entry into cells is a complex one, involving a broad range of host proteins. Entry is a critical phase of the viral lifecycle, and a potential target for therapeutic or vaccine-mediated intervention. However, the mechanics of HCV entry remain poorly understood. Here we describe a novel computational model of viral entry, encompassing the relationship between HCV and the key host receptors CD81 and SR-B1. We conduct experiments to thoroughly quantify the influence of an increase or decrease in receptor availability upon the extent of viral entry. We use these data to build and parameterise a mathematical model, which we then validate by further experiments. Our results are consistent with sequential HCV-receptor interactions, whereby initial interaction between the HCV E2 glycoprotein and SR-B1 facilitates the accumulation CD81 receptors, leading to viral entry. However, we also demonstrate that a small minority of viruses can achieve entry in the absence of SR-B1. Our model estimates the impact of the different obstacles that viruses must surmount to achieve entry; among virus particles attaching to the cell surface, around one third of viruses accumulate sufficient CD81 receptors, of which 4-8% then complete the subsequent steps to achieve productive infection. Furthermore, we make estimates of receptor stoichiometry; in excess of 10 receptors are likely to be required to achieve viral entry. Our model provides a tool to investigate the entry characteristics of HCV variants and outlines a framework for future quantitative studies of the multi-receptor dynamics of HCV entry.

Citing Articles

An entropic safety catch controls hepatitis C virus entry and antibody resistance.

Stejskal L, Kalemera M, Lewis C, Palor M, Walker L, Daviter T Elife. 2022; 11.

PMID: 35796426 PMC: 9333995. DOI: 10.7554/eLife.71854.


Identifying cell-to-cell variability in internalization using flow cytometry.

Browning A, Ansari N, Drovandi C, Johnston A, Simpson M, Jenner A J R Soc Interface. 2022; 19(190):20220019.

PMID: 35611619 PMC: 9131125. DOI: 10.1098/rsif.2022.0019.


In vitro adaptation and characterization of attenuated hypervariable region 1 swap chimeras of hepatitis C virus.

Olesen C, Augestad E, Troise F, Bukh J, Prentoe J PLoS Pathog. 2021; 17(7):e1009720.

PMID: 34280245 PMC: 8321405. DOI: 10.1371/journal.ppat.1009720.


Mechanisms of Hepatitis C Virus Escape from Vaccine-Relevant Neutralizing Antibodies.

Velazquez-Moctezuma R, Augestad E, Castelli M, Olesen C, Clementi N, Clementi M Vaccines (Basel). 2021; 9(3).

PMID: 33804732 PMC: 8004074. DOI: 10.3390/vaccines9030291.


Targeting TMPRSS2 and Cathepsin B/L together may be synergistic against SARS-CoV-2 infection.

Padmanabhan P, Desikan R, Dixit N PLoS Comput Biol. 2020; 16(12):e1008461.

PMID: 33290397 PMC: 7748278. DOI: 10.1371/journal.pcbi.1008461.


References
1.
Zeisel M, Koutsoudakis G, Schnober E, Haberstroh A, Blum H, Cosset F . Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81. Hepatology. 2007; 46(6):1722-31. DOI: 10.1002/hep.21994. View

2.
Ribeiro R, Li H, Wang S, Stoddard M, Learn G, Korber B . Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate. PLoS Pathog. 2012; 8(8):e1002881. PMC: 3426522. DOI: 10.1371/journal.ppat.1002881. View

3.
Padmanabhan P, Dixit N . Inhibitors of hepatitis C virus entry may be potent ingredients of optimal drug combinations. Proc Natl Acad Sci U S A. 2017; 114(23):E4524-E4526. PMC: 5468610. DOI: 10.1073/pnas.1704531114. View

4.
Catanese M, Uryu K, Kopp M, Edwards T, Andrus L, Rice W . Ultrastructural analysis of hepatitis C virus particles. Proc Natl Acad Sci U S A. 2013; 110(23):9505-10. PMC: 3677472. DOI: 10.1073/pnas.1307527110. View

5.
Grove J, Hu K, Farquhar M, Goodall M, Walker L, Jamshad M . A new panel of epitope mapped monoclonal antibodies recognising the prototypical tetraspanin CD81. Wellcome Open Res. 2017; 2:82. PMC: 5657224. DOI: 10.12688/wellcomeopenres.12058.1. View